| Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients A Vijenthira, IY Gong, TA Fox, S Booth, G Cook, B Fattizzo, F Martín-Moro, ... Blood, The Journal of the American Society of Hematology 136 (25), 2881-2892, 2020 | 595 | 2020 |
| Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients W Barcellini, B Fattizzo, A Zaninoni, T Radice, I Nichele, E Di Bona, ... Blood, The Journal of the American Society of Hematology 124 (19), 2930-2936, 2014 | 371 | 2014 |
| Clinical applications of hemolytic markers in the differential diagnosis and management of hemolytic anemia W Barcellini, B Fattizzo Disease markers 2015, 2015 | 315 | 2015 |
| Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies W Barcellini, F Zaja, A Zaninoni, FG Imperiali, ML Battista, E Di Bona, ... Blood, The Journal of the American Society of Hematology 119 (16), 3691-3697, 2012 | 157 | 2012 |
| Cold agglutinin disease revisited: a multinational, observational study of 232 patients S Berentsen, W Barcellini, S D’Sa, U Randen, THA Tvedt, B Fattizzo, ... Blood, The Journal of the American Society of Hematology 136 (4), 480-488, 2020 | 115 | 2020 |
| The changing landscape of autoimmune hemolytic anemia W Barcellini, B Fattizzo Frontiers in immunology 11, 534738, 2020 | 110 | 2020 |
| Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long‐term response M Marangon, N Vianelli, F Palandri, MG Mazzucconi, C Santoro, ... European Journal of Haematology 98 (4), 371-377, 2017 | 97 | 2017 |
| New insights in autoimmune hemolytic anemia: from pathogenesis to therapy W Barcellini, A Zaninoni, JA Giannotta, B Fattizzo Journal of clinical medicine 9 (12), 3859, 2020 | 91 | 2020 |
| How I treat warm autoimmune hemolytic anemia W Barcellini, B Fattizzo Blood, The Journal of the American Society of Hematology 137 (10), 1283-1294, 2021 | 80 | 2021 |
| Sustained response to low‐dose rituximab in idiopathic autoimmune hemolytic anemia W Barcellini, F Zaja, A Zaninoni, FG Imperiali, E Di Bona, B Fattizzo, ... European Journal of Haematology 91 (6), 546-551, 2013 | 78 | 2013 |
| Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study G Rossi, D Gramegna, F Paoloni, B Fattizzo, F Binda, M D’Adda, M Farina, ... Blood, The Journal of the American Society of Hematology 132 (5), 547-550, 2018 | 71 | 2018 |
| Autoimmune cytopenias in chronic lymphocytic leukemia: focus on molecular aspects B Fattizzo, W Barcellini Frontiers in Oncology 9, 1435, 2020 | 61 | 2020 |
| Predictors of refractoriness to therapy and healthcare resource utilization in 378 patients with primary autoimmune hemolytic anemia from eight Italian reference centers W Barcellini, A Zaninoni, B Fattizzo, JA Giannotta, M Lunghi, A Ferrari, ... American Journal of Hematology 93 (9), E243-E246, 2018 | 61 | 2018 |
| Current and emerging treatment options for autoimmune hemolytic anemia W Barcellini, B Fattizzo, A Zaninoni Expert review of clinical immunology 14 (10), 857-872, 2018 | 60 | 2018 |
| The physiopathology of T-cell acute lymphoblastic leukemia: focus on molecular aspects B Fattizzo, J Rosa, JA Giannotta, L Baldini, NS Fracchiolla Frontiers in oncology 10, 273, 2020 | 59 | 2020 |
| Efficacy of recombinant erythropoietin in autoimmune hemolytic anemia: a multicenter international study B Fattizzo, M Michel, A Zaninoni, JA Giannotta, S Guillet, H Frederiksen, ... Haematologica 106 (2), 622, 2021 | 53 | 2021 |
| Management of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: current perspectives W Barcellini, B Fattizzo, A Zaninoni Journal of blood medicine, 265-278, 2019 | 51 | 2019 |
| Autoimmune hemolytic anemia in adults: primary risk factors and diagnostic procedures W Barcellini, J Giannotta, B Fattizzo Expert Review of Hematology 13 (6), 585-597, 2020 | 49 | 2020 |
| Eltrombopag in immune thrombocytopenia, aplastic anemia, and myelodysplastic syndrome: from megakaryopoiesis to immunomodulation B Fattizzo, G Levati, R Cassin, W Barcellini Drugs 79 (12), 1305-1319, 2019 | 49 | 2019 |
| Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia B Fattizzo, R Ireland, A Dunlop, D Yallop, S Kassam, J Large, S Gandhi, ... Leukemia 35 (11), 3223-3231, 2021 | 48 | 2021 |
